Outcomes of Patients ≥ 65 Years of Age in Zuma-1, a Pivotal Phase 1/2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Refractory Large B Cell Lymphoma
Hematological Oncology - United Kingdom
doi 10.1002/hon.112_2630
Full Text
Open PDFAbstract
Available in full text
Date
June 1, 2019
Authors
Publisher
Wiley